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ABSTRACT
Objective To determine whether plasma cystatin C and
creatinine levels after isolated off-pump coronary artery
bypass grafting (OPCAB) are predictive of postoperative
renal dysfunction and clinical outcomes.
Methods Between January 2008 and December 2013,
1033 who underwent isolated OPCAB were recruited.
The patients were divided into three groups according to
the preoperative level of cystatin C: low (0.83 mg/L>),
mid (0.83–1.13 mg/L) and high (1.13 mg/L<). The
endpoints of all-cause mortality and major adverse
cerebrovascular and cardiovascular events were
compared among three groups using the Kaplan–Meier
method. The predictive power of cystatin C was
compared with creatinine using receiver operating curves.
Results Follow-up was complete in all of the included
patients at a mean of 2.9±1.5 years. Within the follow-
up period, 9 early (30-day mortality) and 46 late deaths
occurred. The 30-day mortality was zero, four (44%),
and ﬁve (56%) cases in low, mid and high groups,
respectively (p=0.03). The cut-off value of cystatin C
for renal dysfunction prediction was approximately
1.04 (mg/L, p<0.001), and cystatin C showed greater
predictive power than creatinine for renal dysfunction
(area under the curve=0.73 vs 0.65; p=0.01). One-year
and ﬁve-year overall survival in low, mid and high
groups were 99.2%, 98.9% and 94.3%, and 97.9%,
97.3% and 86.3%, respectively (low vs high, p=0.01).
Conclusions Cystatin C is a stronger predictor of
postoperative renal dysfunction than serum creatinine,
and its level is directly correlated with mid-term OPCAB
adverse results.
INTRODUCTION
Postoperative renal dysfunction affects 1–5% of
patients who have undergone cardiac surgery and
remains a leading cause of morbidity and mortality
in this patient group.1–3 Regardless of the various
pathophysiologies of renal injury, its two main
aetiologies are as follows: perioperative renal
hypoperfusion and the presence of endogenous
and exogenous nephrotoxins (free radicals,
pro-inﬂammatory cytokines, circulating catechola-
mines, anaesthetic agents and contrast media).
These factors can induce glomerular and tubular
injury, especially in the presence of comorbidities
(eg, preoperative renal dysfunction, diabetes melli-
tus, impaired left ventricular function and
advanced age). Because of the key role renal dys-
function plays in predicting the outcomes of
cardiac surgery and the patient’s prognosis, it is
important that surgeons have a realistic preopera-
tive understanding of renal dysfunction risk
factors. One of the most important determinants
for AKI is the patient’s preoperative renal reserve
determined by preoperative assessment of kidney
function.2 4 5 Serum creatinine concentration is
the most useful and widely used determinant for
renal dysfunction.
Although serum creatinine concentration remains
the clinical standard for renal dysfunction diagno-
sis, it may not be ideal because creatinine is an
inaccurate measure of glomerular ﬁltration. A small
proportion of creatinine is secreted in urine
without being ﬁltered, and serum creatinine levels
are dependent on its generation from muscle mass,
which may be reduced in the postoperative
setting.6 In recent studies, serum cystatin C has
been featured as an easily measurable marker of
kidney function that is less inﬂuenced by non-
glomerular ﬁltration rate (GFR) determinants, such
as muscle mass, and it is eliminated solely by glom-
erular ﬁltration.7 8 However, few studies have eval-
uated the predictive power of cystatin C in adult
cardiac surgery, particularly procedures with
off-pump coronary bypass (OPCAB), although the
postoperative cystatin C level did show a positive
correlation with surgical outcomes in paediatric
cardiac surgery patients.8
The aim of this study was determine whether
cystatin C and creatinine are predictive of renal
dysfunction and evaluate their prognostic value for
clinical outcomes after OPCAB.
METHODS
Study population
A total of 1418 consecutive patients undergoing
isolated OPCAB at Severance Cardiovascular
Hospital, Yonsei University Health System, from
January 2008 to December 2013 were identiﬁed
retrospectively. Of these patients, 385 were
excluded; in 210 of these patients, the serum cysta-
tin C level had not been evaluated preoperatively,
and 175 met the following exclusion criteria: emer-
gency operation, preoperative serum creatinine
≥3.0 mg/dL (or on dialysis) surgery under cardio-
pulmonary bypass or concomitant valve surgery,
missing or incomplete record case. A total of 1033
who underwent isolated OPCAB were recruited
ﬁnally. Blood samples were collected preoperatively
and on the ﬁrst, second, fourth and seventh days
postoperatively to measure serum cystatin C and
creatinine in all of the included patients.
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Previous studies for evaluating the cystatin C as a predictor of
renal function in various situations showed the guiding and ref-
erence value. Cystatin C level 1.13 (mg/L) is a usual value for
the worst categorisation that represent the 20% of participants
with the highest cystatin C level and 0.83 (mg/L) represented
20% of participants with the lowest cystatin C level.9 10 So we
categorised our cohort into three groups according to the pre-
operative serum cystatin C level, deﬁned as low (<0.83 mg/L),
mid (0.83–1.13 mg/L) and high (>1.13 mg/L). ‘High’ repre-
sented the 20% of participants with the highest cystatin C level
and the highest creatinine level. All baseline and clinical
characteristics were obtained from the medical record of
patients.
Operative technique
The operative technique and graft strategy have been previously
described.11 Brieﬂy, the operation was performed through a full
sternotomy incision or minimal incision through the left ﬁfth
intercostal space, and the left internal mammary artery was har-
vested in a semi-skeletonised fashion. The second choice of
graft was the radial artery, which was harvested with a
Harmonic scalpel (Ethicon Endosurgery, Cincinnati, Ohio,
USA). The right internal mammary artery, saphenous vein or
right gastroepiploic artery was also harvested, if necessary.
Heparin (0.7–1.0 mg/kg) was administered to achieve a target
activated clotting time (≥300 s) before ligation of the distal
internal mammary artery. Target arteries were stabilised with a
tissue stabiliser and heart positioner. During anastomosis, blood
was removed from the arteriotomy sites with a misted carbon
dioxide blower, and the area was irrigated with warm saline.
After surgery, the patients were transferred to the intensive care
unit and managed as usual.
Deﬁnition of renal dysfunction and transformation formula
of estimation of GFR
Renal dysfunction is deﬁned as any of the following: (1) an
increase in serum creatinine ≥0.3 mg/dL (≥26.5 μmol/L) within
48 h, (2) an increase in serum creatinine to ≥1.5 times
baseline, which is known or presumed to have occurred
within the prior 7 days, and (3) a urine volume <0.5 mL/kg/h
for 6 h.12 We used our hospital transformation formula of esti-
mated GFR as follows: (1) creatinine-based estimation of
GFR=175×(Scr)−1.154×(Age)−0.203×(0.742 if female); and
(2) cystatin-based estimation of GFR=84.69×cystatin C
(mg/L)−1.680×1.384* (* for children <14 years).
Statistical analysis
Categorical variables, presented as frequencies and percentages,
were compared using the χ2 test. Continuous variables,
expressed as the mean±SD or the median with a range as
appropriate, were compared using Student’s t test. The Kaplan–
Meier method was used to delineate the overall survival rate
and mortality and major adverse cerebrovascular and cardiovas-
cular events (MACCEs), and the log-rank test was used to
compare the differences in the rates between low, mid and high
groups.
The incidences of renal dysfunction were calculated by the
quintile of each of the two kidney function measures. We com-
pared the strength and independence of the association between
each kidney function measure and the renal dysfunction across
the best, intermediate and worst groups. We used multivariate
logistic regression analyses to determine the associations of
kidney function categories according to cystatin C with major
adverse cerebrovascular and cardiovascular events MACCEs.
The models were adjusted for demographics, comorbid condi-
tions and procedural variables, as listed above.
To evaluate the predictability of each kidney function test
(cystatin C level and creatinine level) on risk discrimination, we
constructed receiver operating characteristic curves and calcu-
lated the C statistic (area under the curve (AUC)). The C statistic
was compared for each variable to determine the predictability
of MACCEs and renal complications. All reported p values were
two-sided, and a value of p<0.05 was considered statistically
signiﬁcant. SPSS V.18.0 (IBM Corp., Armonk, New York, USA)
Table 1 Baseline characteristics and operative data
Variables* Low (n=278) (0.83 mg/L >) Mid (n=519) (0.83–1.13 mg/L) High (n=236) (1.13 mg/L<) p Value
Age (years) 60.9±9.6 65.5±8.3 69.8±9.1 0.01
Females (n, %) 62 (24%) 109 (24%) 56 (28%) 0.53
HTN (n, %) 163 (64%) 329 (73%) 167 (84%) 0.01
DM (n, %) 90 (35%) 177 (40%) 106 (54%) 0.01
Dyslipidemia (n, %) 162 (64%) 178 (40%) 66 (34%) 0.21
CVA (n, %) 16 (6%) 33 (7%) 34 (17%) 0.01
COPD (n, %) 3 (1%) 9 (2%) 10 (5%) 0.02
PAOD (n, %) 13 (5%) 26 (6%) 30 (15%) 0.01
EuroSCORE 3.2±2.3 3.9±2.3 5.7±3.8 0.01
NYHA (3≤n, %) 47 (17%) 98 (19%) 72 (31%)
LVEF (%) 58.5±13.0 57.3±14.7 51.5±14.7 0.01
LVESD (mm) 35±7.5 35.8±8.3 37.4±8.7 0.01
LVEDD (mm) 50.5±6.6 50.7±7.3 51.3±8.2 0.57
Distal anastomosis (n) 3.2±0.9 3.2±0.8 3.6±0.8 0.52
LIMA usage (n, %) 246 (96%) 438 (98%) 195 (99%) 0.76
C.R. (n, %) 230 (90%) 413 (92%) 180 (91%) 0.81
Operation time (min) 229.4±41.3 235.6±46.3 232.3±42.8 0.21
*Data for continuous variables are shown as mean±SD (range) and data for categorical variables as number (%).
CR, complete revascularisation; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DM, diabetes mellitus; EuroSCORE, European System for Cardiac Operative
Risk Evaluation; HTN, hypertension; LIMA, left internal mammary artery; LVEDD, LV end-diastolic dimension; LVESD, LV end-systolic dimension; NYHA, New York Heart Association;
PAOD, peripheral artery occlusive disease.
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and MedCalc (MedCalc Software, Ostend, Belgium) were used
for the statistical analyses.
RESULTS
Baseline characteristics and in-hospital outcomes
The baseline demographic, echocardiography and other pre-
operative parameters are detailed in table 1. The baseline
characteristics were compared across the three groups. In
summary, patients in the high group tended to be older. In add-
ition, diabetes mellitus, hypertension, cerebrovascular attacks
and peripheral artery obstructive diseases were more common in
the high group. However, the number of distal anastomosis (low
group 3.2±0.9, mid group 3.2±0.8 and high group 3.1±0.8,
p=0.52) and length of the operation in minutes (low group
229.4±41.3, mid group 235.6±46.3 and high group 232.3
±42.8, p=0.21) were not signiﬁcantly different among groups.
Clinical events: morbidity and mortality outcomes
We compared the clinical outcomes among the three groups
deﬁned by cystatin C levels. Follow-up was complete in all of
the included patients at a mean of 35.2±18.1 months (IQR
22.9—51.0 months), during which time there were 9 early
(30-day mortality) and 46 late deaths. The 30-day mortality was
zero, four (44%) and ﬁve (56%) cases in the low, mid and high
groups, respectively (p=0.034) (table 2).
In our evaluation of the sensitivity of each kidney function
test (cystatin C level and creatinine level) on risk discrimination,
the cut-off value of cystatin C for predicting mortality was 1.04
(ﬁgure 1). Cystatin C proved to be a more powerful predictor
for postoperative renal dysfunction than serum creatinine
(ﬁgure 2). We found that converting the estimated GFR (eGFR)
produced a value more sensitive for predicting adverse renal
dysfunction. Both eGFR converted from the cystatin C and cre-
atinine increased the AUC value rather than pre-converting
value, and of these two, the most sensitive predictor was the
cystatin-based eGFR (AUC=0.733, CI 0.70 to 0.760). However,
cystatin was not a statistically signiﬁcant predictor of mortality
(AUC 0.73 vs 0.70, p=0.47) or MACCEs (AUC 0.61 vs 0.62,
p=0.91) compared with creatinine (ﬁgure 3).
The overall survival rates at 1, 3 and 5 years were 99%, 98%
and 97% in the low group, 98%, 97% and 97% in the mid
group, and 94%, 86% and 86% in the high group log-rank test,
low vs high group, p<0.001, respectively, using the Kaplan–
Meier method. The freedom from MACCEs showed result
similar to that of the overall survival rate between the low and
high groups (log-rank test, p<0.001) (ﬁgure 4).
Univariate and multivariate Cox regression analyses were used
to assess the predictors of mortality and other adverse events.
After adjustment for preoperative baseline characteristics and
age, category high group (cystatin C >1.13 mg/L) was inde-
pendently related to mortality and MACCEs. The odds ratio for
mortality according to age and across all groups was 1.10 (95%
CI 1.03 to 1.17, p<0.001) and 0.35 (95% CI 0.14 to 0.83,
p=0.02) (table 3), respectively. We also found that the cystatin-
based eGFR and plasma cystatin C category (high group) were
statistically signiﬁcant factors for predicting postoperative renal
dysfunction (table 4).
DISCUSSION
Postoperative renal dysfunction is one of the critical complica-
tions of cardiac surgery. Not only does renal dysfunction lead to
an increased in-hospital mortality risk, but it also predisposes
the patient to long-term mortality risk, even among those who
appear to recover from the renal dysfunction.13 14 However,
little is known about the sensitivity and speciﬁcity of renal dys-
function predictive factors. In clinical practice, serum creatinine
is the most commonly used parameter for the assessment of
renal function, although it has many limitations. It has a low
sensitivity, and its assay is inﬂuenced by numerous factors,
resulting in wide inter-individual variability.
Cystatin C is a cysteine protease inhibitor produced by all
nucleated cells. It is a non-glycosylated low-molecular-weight
plasma protein (13 kDa).15 As glomerular ﬁltration is the only
Table 2 Operative outcomes after stratification for cystatin C level
Low (n=278) Mid (n=519) High (n=236) p Value
Early result (30 days>)
Wound complications (n, %) 3 (1.08) 12 (2.31) 4 (1.69) 0.43
Neurological complications (n, %) 4 (1.44) 6 (1.16) 2 (0.84) 0.85
Delayed ventilation (48 h<, n, %) 5 (1.80) 33 (6.36) 20 (8.47) 0.01
Renal dysfunction (n, %) 15 (5.04) 44 (75.88) 72 (30.5) 0.01
Mortality (30 days) 0 (0) 4 (0.8) 5 (2.1) 0.03
Figure 1 Receiver operating characteristic (ROC) curve of cystatin C
and cut-off value for prediction of renal dysfunction. ROC plots of
serum cystatin C demonstrated the area under the curve (AUC) for
renal dysfunction (AUC=0.73, CI 0.70 to 0.75, p<0.001). The cut-off
value for maximising AUC (or the Yoden index) of AKI was 1.04 mg/L.
Renal dysfunction is deﬁned as any of the following: (1) an increase
in serum creatinine ≥0.3 mg/dL (≥26.5 μmol/L) within 48 h; (2) an
increase in serum creatinine to ≥1.5 times baseline, which is known
or presumed to have occurred within the prior 7 days; and (3) a urine
volume<0.5 mL/kg/h for 6 h.12
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elimination pathway of cystatin C, its serum concentration has
been used to estimate GFR in various experimental and clinical
settings.16 Cystatin C can be measured from a spot serum sample
and avoids the meticulous urine sample collections necessary for
estimating creatinine clearance. Its assay is less susceptible to the
methodological interference inherent in the routine method of
creatinine estimation. In addition, cystatin C has less inter-
individual variation than serum creatinine, allowing for earlier
detection of impairment in renal function.17 Therefore, if it is
possible to take a sample of either from preoperative patients,
sampling cystatin C would be more effective for predicting post-
operative renal dysfunction or late surgical outcomes. In several
recent studies, cystatin C has been suggested as an early indicator
of impaired renal function and may be superior to serum creatin-
ine in terms of diagnostic accuracy for reduced GFR.18–20 In
addition, it has been reported to be a more sensitive marker of
changes in GFR than serum creatinine.21
Serum cystatin C has been also shown to be more sensitive
and speciﬁc than creatinine in a variety of clinical settings.16 22
A theoretical reduction in the incidence and severity of post-
operative renal impairment has been proposed by eliminating
factors related to the use of cardiopulmonary bypass, especially
in high-risk patients,23 24 but the current evidence for off-pump
surgery reducing postoperative renal dysfunction is conﬂicting.25
The evidence of the relationship between clinical outcomes of
isolated OPCAB including renal impairment and serum cystatin
C remains unknown, and it is also unclear which renal function
assessment value (cystatin C vs creatinine) is more sensitive and
speciﬁc for predicting renal dysfunction in OPCAB.
Therefore, we focused on clarifying the predictive power of
serum cystatin C using discrete categories, and then comparing
the ability of these discrete categories to the power of cystatin
C, creatinine and demographic factors for the prediction of
clinical outcomes including renal dysfunction, mortality and
MACCEs in OPCAB patients. Among the variables tested, age
(p<0.01) and high plasma cystatin C (p=0.04) proved to be
signiﬁcant predictors for decreased mortality and MACCEs. For
predicting renal dysfunction, cystatin C-based eGFR (p=0.03)
and serum cystatin C serum level group (p=0.01) were mean-
ingful factors. We also looked for a cut-off value for cystatin C
using receiver operating characteristic plotting and compared
the predictive strength of the two renal function assessment
values.
Figure 2 Area under the curve (AUC) comparison among cystatin C,
creatinine, cystatin C-based estimated glomerular ﬁltration rate (eGFR)
and creatinine-based eGFR for renal dysfunction. Cystatin C proved to
be a more powerful predictor for postoperative renal complication than
serum creatinine. We found that converting the eGFR produced a value
more sensitive for predicting renal dysfunction. Both eGFR converted
from the cystatin C and creatinine increased the AUC value rather than
pre-converting value, and of these two, the most sensitive predictor
was the cystatin-based eGFR (AUC=0.733, CI 0.70 to 0.760).
Figure 3 (A) Area under the curve (AUC) comparison between cystatin C and creatinine for mortality. (B) AUC comparison between cystatin C
and creatinine for major adverse cerebrovascular and cardiovascular events (MACCEs). Follow-up duration was a mean of 35.2±18.1 months
(IQR 22.9–51.0 months). A MACCE was deﬁned as the occurrence of death, non-fatal myocardial infarction, stroke and target vessel
revascularisation.
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Receiver operating characteristic plots of serum cystatin C
demonstrated that the AUC for renal dysfunction (AUC=0.73,
CI 0.70 to 0.75, p<0.001) and for overall mortality
(AUC=0.73, CI 0.70 to 0.76, p<0.001) were both statistically
signiﬁcant. The cut-off value for maximising AUC (or the Yoden
index) of renal dysfunction was 1.04 mg/L (ﬁgure 1).
By deﬁnition, the group high had a cystatin C level of
>1.13 mg/L, and the group’s preoperative average creatinine
level was 1.4±0.8 mmol/L (low group: 0.9±0.2 and mid group:
1.0±0.2; F value=139, p<0.001). However, this creatinine
level was relatively lower than the level of creatinine generally
known to be abnormal (>1.5 mmol/L). This gap between cysta-
tin C and creatinine was probably a clue about the difference in
their predictive power, so we compared the AUC value of each
kidney assessment factor for renal dysfunction. We found that
cystatin C showed a greater tendency to predict mortality
Figure 4 (A) Overall survival rate (%) according to cystatin C level. (B) Free from major adverse cerebrovascular and cardiovascular events rate (%)
according to cystatin C level. Category deﬁnitions: low: 0.83 mg/L >; mid: 0.83–1.13 mg/L; high: 1.13 mg/L<.
Table 3 Univariate and multivariate analysis for risk analysis of mortality and major adverse cerebrovascular and cardiovascular events
(MACCEs)
Mortality MACCEs
Univariate Multivariate Univariate Multivariate
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Age 1.15 (1.09 to 1.21) 0.01 1.10 (1.03 to 1.17) 0.01 1.06 (1.03 to 1.08) 0.01 1.05 (1.01 to 1.08) 0.01
Female 0.81 (0.43 to 1.53) 0.52 0.95 (0.60 to 1.51) 0.81
Weight 0.98 (0.95 to 1.00) 0.09 0.99 (0.96 to 1.03) 0.84 0.99 (0.97 to 1.01) 0.28 0.98 (0.95 to 1.02) 0.35
DM 0.78 (0.44 to 1.40) 0.40 1.15 (0.75 to 1.77) 0.52
Dyslipidemia 0.42 (0.21 to 0.84) 0.01 0.44 (0.21 to 0.92) 0.03 1.18 (0.76 to 1.82) 0.46
Last creatinine 1.96 (1.51 to 2.42) 0.01 1.40 (0.82 to 2.37) 0.22 1.59 (1.26 to 2.01) 0.01 1.41 (0.91 to 2.17) 0.13
Creatinine-based eGFR 0.97 (0.96 to 0.98) 0.01 0.99 (0.97 to 1.02) 0.58 0.99 (0.98 to 0.99) 0.01 1.04 (0.99 to 1.09) 0.11
PAOD 0.27 (0.14 to 0.53) 0.01 2.25 (1.08 to 4.70) 0.03 0.42 (0.24 to 0.73) 0.02 0.53 (0.25 to 1.12) 0.10
EuroSCORE 1.08 (1.05 to 1.12) 0.01 1.0 (0.93 to 1.08) 0.92 1.06 (1.03 to 1.10) 0.01 1.01 (0.94 to 1.08) 0.84
CHF 1.82 (0.56 to 5.89) 0.32 1.64 (0.59 to 4.54) 0.34
Arrhythmia 1.69 (0.52 to 5.50) 0.38 2.51 (1.08 to 5.85) 0.03 0.37 (0.14 to 0.99) 0.37
NYHA (III≤) 0.50 (0.04 to 6.86) 0.60 0.64 (0.06 to 7.05) 0.71
LVEF 0.98 (0.96 to 1.0) 0.02 0.98 (0.96 to 1.00) 0.10 0.99 (0.98 to 1.00) 0.1
Distal anastomosis 1.10 (0.78 to 1.54) 0.60 1.14 (0.84 to 1.56) 0.4
Pre. CK-MB 0.99 (0.98 to 1.02) 0.90 1.00 (0.99 to 1.01) 0.71
Pre. cystatin C 1.01 (0.96 to 1.07) 0.65 1.01 (0.95 to 1.07) 0.78
Cystatin C-based eGFR 0.97 (0.956 to 0.980) 0.01 0.98 (0.96 to 1.01) 0.24 0.99 (0.98 to 0.99) 0.01 0.99 (0.97 to 1.00) 0.58
Group
Mid vs low 1.14 (0.38 to 3.48) 0.80 0.37 (0.11 to 1.24) 0.11 1.06 (0.44 to 2.55) 0.89 0.65 (0.24 to 1.75) 0.39
High vs low 7.10 (2.64 to 19.12) 0.01 0.35 (0.14 to 0.83) 0.02 4.20 (1.86 to 9.46) 0.01 0.47 (0.21 to 1.03) 0.04
*p<0.05.
CHF, congestive heart failure; CK, creatine kinase; DM, diabetes mellitus; EDD, end-diastolic dimension; eGFR, estimated glomerular filtration rate; ESD, end-systolic dimension;
EuroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New York Heart Association; PAOD, peripheral artery occlusive disease.
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compared with creatinine (AUC 0.73 vs 0.65, p=0.003) and
renal dysfunction (AUC 0.80 vs 0.75, CI −0.016 to 0.111,
p=0.15), but the difference was not statistically signiﬁcant. We
also found that 1.05 mg/L of cystatin C was the cut-off value for
maximising AUC (or the Yoden index) of mortality.
Wang et al26 demonstrated the potential usefulness of cystatin
C as a test for detecting early changes of GFR in patients after
coronary artery bypass grafting (CABG).26 As described in their
previous studies,25 27 changes in the cystatin C concentration
paralleled those of GFR. Of all the available markers, cystatin C
had the best correlation with GFR. Cystatin C was more accur-
ate and reﬂected the changes in GFR with greater
sensitivity.21 28
Several other studies in various settings have determined that
the cystatin C level has much strong associations with cardiovas-
cular and other clinical outcomes in ambulatory patients.29 30
One recent study of 150 patients from three academic medical
centres found that the cystatin C level was a stronger predictor
of postsurgical renal dysfunction than was the creatinine level.
The ability of cystatin C to predict renal dysfunction was corre-
lated with its strong association with mortality, so the preopera-
tive cystatin C level might be a prognostic factor for surgical
clinical outcomes including mortality.
Despite several studies about the reno-protective effect of
OPCAB, few studies have sought to determine the clinical cor-
relation between cystatin C and OPCAB clinical outcomes
including renal dysfunction. A prospective randomised com-
parison of 200 unselected patients undergoing off-pump versus
conventional CABG reported no difference in the postoperative
incidence of renal failure between the two groups.31 However,
several large observational studies including a higher proportion
of high-risk patients have reported a signiﬁcant reduction in
the frequency of renal failure in patients undergoing
OPCAB24 32 33 Based on these results, using the cystatin C
check preoperatively, we might be able to anticipate renal dys-
function and prevent it by more aggressive postoperative inten-
sive care management as well as predict surgical clinical
outcomes. In our result using univariate and multivariate Cox
regression analysis, high cystatin C (>1.15 mg/L) was a signiﬁ-
cant risk factor for overall mortality and renal dysfunction.
Therefore, cystatin C might be used not only to predict renal
dysfunction but also to establish a mortality prognosis of iso-
lated OPCAB patients.
LIMITATIONS
There were several limitations to this study. Our cohort of
patients was not randomised, and the three groups were not
precisely matched because of missing data. Adjustment for the
differences among the three groups might be important to
reduce bias in the estimates obtained (so we performed stratiﬁed
analysis according to age category for minimising this bias; see
online supplementary table). Another limitation was the rela-
tively short follow-up period of just 35 months. A longer
follow-up period may yield more results in terms of
post-OPCAB mortality and morbidity, which in turn may help
to further elucidate the role of cystatin C in predicting adverse
cardiac events after OPCAB.
CONCLUSIONS
Cystatin C was a stronger predictor of renal dysfunction and
mid-term mortality than serum creatinine. It was also a power-
ful predictor of the risk of MACCEs. Patients with a plasma
cystatin C level >1.13 mg/L seem to have an increased risk of
mortality, MACCEs and postoperative renal dysfunction.
Therefore, preoperative measurement of cystatin C has potential
utility for risk stratiﬁcation of renal dysfunction and might be
an important predictor for the clinical outcomes following
OPCAB.
Key messages
What is already known on this subject?
Until now, preoperative serum creatinine level was the strongest
factor to predict a postoperative renal function status regardless
of cardiac surgery types.
What might this study add?
In the present study, we found stronger prediction factor
(cystatin C) for postoperative renal function status. Using this
factor, we prevent postoperative renal dysfunction by adequate
management before worsening of kidney.
How might this impact on clinical practice?
In off-pump coronary artery bypass grafting surgery,
postoperative renal function is strongly associated with late
survival and clinical results. Therefore, we should prevent renal
dysfunction before worsening of kidney status. From this
predictive value (cystatin C), we prepare proper management of
renal dysfunction.
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Age 1.06 (1.03 to 1.08) 0.01 1.02 (0.99 to 1.05) 0.15
Female 0.58 (0.41 to 0.83) 0.01 0.83 (0.50 to 1.39) 0.48
Weight 0.97 (0.96 to 0.99) 0.01 1.00 (0.98 to 1.02) 0.98
Smoker 1.00 (0.71 to 1.42) 0.99
DM 0.53 (0.37 to 0.74) 0.01 0.63 (0.42 to 0.94) 0.02
Dyslipidemia 1.27 (0.88 to 1.82) 0.19
Last creatinine 1.39 (1.15 to 1.69) 0.01 1.22 (0.82 to 1.82) 0.34
Creatinine-based
eGFR
0.99 (0.98 to 0.99) 0.01 1.02 (1.01 to 1.03) 0.01
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Pre. cystatin C 1.01 (0.98 to 1.04) 0.04 0.96 (0.86 to 1.07) 0.45
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eGFR
3.66 (2.79 to 4.80) 0.01 0.98 (0.96 to 0.99) 0.03
Group
Low vs mid 1.14 (0.38 to 3.48) 0.8 0.37 (0.11 to 1.24) 0.11
Low vs high 7.10 (2.64 to 19.12) 0.01 0.35 (0.14 to 0.83) 0.02
*p<0.05.
COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; EuroSCORE: European System for Cardiac Operative Risk
Evaluation; LVESD, LV end-systolic dimension; NYHA, New York Heart Association;
PAOD, peripheral artery occlusive disease.
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